Abstract A011: ATM inhibitors exploit checkpoint defects and ATM-dependent double strand break repair to induce mitotic cell death in TP53-mutant glioblastoma
Daniel J. Laverty(Massachusetts Department of Public Health), Zachary D. Nagel(Harvard University), Shiv K. Gupta(Mayo Clinic), Brett L. Carlson(University of California, San Francisco), Nery Matias Calmo(Harvard University), Jiajia Chen(Peking University Shougang Hospital), Jann N. Sarkaria(Mayo Clinic in Arizona), Shulan Tian(Mayo Clinic), Gary A. Bradshaw(Harvard University)
Cited by 0
Related Papers
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
|Molecular Cancer Therapeutics|2007|203
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
|British Journal of Cancer|2011|193